Erbitux Open-label Results For NSCLC Hardly Stellar
This article was originally published in The Pink Sheet Daily
Executive Summary
Still, the BMS-099 study supports results of the much larger and better-powered FLEX study, ImClone says.
You may also be interested in...
Mystery Date: ImClone Rejects Bristol For Unnamed $70 Per Share Bidder
Much industry speculation suggests Icahn seeks higher bid from BMS, which initially offered $60 per share.
Mystery Date: ImClone Rejects Bristol For Unnamed $70 Per Share Bidder
Much industry speculation suggests Icahn seeks higher bid from BMS, which initially offered $60 per share.
FLEX Shows Erbitux’s Strength With Survival Benefit In NSCLC
Bristol-Myers Squibb/ImClone/MerckKGaA’s cetuximab significantly prolongs survival in the first-line treatment of NCSLC.